Pharnext Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Research & Development
Dr. Burkhard Blank brings more than 25 years of industry experience and will support the ongoing PREMIER pivotal Phase III trial for lead candidate PXT3003 to treat Charcot-Marie-Tooth Disease Type 1A
United States France General Boehringer Ingelheim Universitaet Marburg Sukaina Virji Ghislaine Gasparetto
Source: finanznachrichten.de